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Introduction: Response rates in the palliative treatment of non-
small cell lung cancer, with combination platinum-based chemother-
apy, vary from 20% to 40%, leaving a large number with either
stable or progressive disease. We examined radiographic response
after two courses of platinum-based induction chemotherapy to see
whether this is an early predictor of outcome.
Methods: In this retrospective study, 320 patients with stage III/IV
NSCLC were identified who received 4 or more courses of first-line
platinum-based chemotherapy and attained partial response (PR) or
stable disease (SD).
Results: After two courses, 115 patients attained PR and 205 SD.
Cox regression analysis shows that response after two courses of
chemotherapy remains an independent significant prognostic factor
for survival. The 2-year survival for patients attaining PR after two
courses (n 115) was 23% compared with 11% (n 205) for those
with SD (p  0.002). Patients who achieve an objective response
after two courses also have a better symptomatic response (p 
0.003) and it was significantly longer (p  0.04). Of the 205 with
SD, 51 attained PR with four courses, whereas 154 (48%) remained
with SD; there was no difference in survival outcome of these two
groups.
Conclusions: These data suggest that NSCLC patients who only
have SD after two cycles of first-line chemotherapy have poorer
survival outcome and less symptomatic benefit than those in PR.
Trials looking at change in management at this point are warranted.
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Multiple randomized trials have established the standardof care for patients with inoperable locally advanced or
metastatic non-small cell lung cancer (NSCLC). Platinum-
based combination chemotherapy is the standard treatment,
with consistent therapeutic superiority in randomized trials
and meta-analyses compared with best supportive care or
single-agent platinum.1,2 Unfortunately, over the past decade,
we have seen a plateau in clinical outcome whereby the
median survival seldom exceeds 8 to 10 months, 1-year
survival rates of 35% to 40% and 2-year survival rates of 10%
to 15% at best.3–6 Attempts to add a third agent to platinum
combinations or to extend treatment beyond four to six cycles
or to institute non–cross-resistant consolidation has yet to
enhance outcome.7–9 Hence, there is a clear-cut need for
either newer treatment approaches with novel agents or op-
timizing the treatment of these patients with the chemother-
apeutic agents that we currently have to attain maximum
therapeutic benefit.
It has recently been shown that sequential therapy with
a platinum two-drug combination followed by a taxane, when
compared with six courses of the same platinum two-drug
combination, did not result in a survival benefit. In this trial,
patients were switched to receive the taxane after three cycles
of the platinum-based chemotherapy.10 A strategy to improve
outcomes from treatment may need to switch patients at an
earlier point. This could be reasonable if we have active
alternative treatments to offer or treatment dictated by the
phenotypic profile. Currently, we assess patients after every
two cycles of chemotherapy, so this is the earliest point at
which we can get information on response. This retrospective
study was an attempt to identify a subset of patients with poor
outcome after two courses of first-line platinum-based che-
motherapy who warrant investigation of new strategies.
PATIENTS AND METHODS
Patients
All patients with histologic or cytologically proven
inoperable locally advanced NSCLC suitable only for pallia-
tive treatment or metastatic NSCLC who had received plati-
num-based chemotherapy as first-line treatment were in-
cluded in the study. Patients received treatment at the Royal
Marsden Hospital between August 1987 and August 2004.
The criteria to commence chemotherapy were ability to give
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signed informed consent to treatment, adequate renal function
assessed with chromium-51 (51-Cr) ethylenediaminetetraace-
tic acid or Cockroft and Gault calculated glomerular filtration
rate, and adequate liver function tests not more than two
times normal unless caused by metastatic disease. Patients
with serious uncontrolled concomitant illness were consid-
ered not eligible to receive chemotherapy.
From a prospectively maintained database, 1041 pa-
tients with stage III–IV NSCLC were identified who received
platinum-based chemotherapy. Of these, 320 patients re-
ceived four or more courses of platinum-based chemotherapy
as first-line treatment and these patients are analyzed in this
paper. The reasons for exclusion for the rest of the patients
were as follows: 637 were excluded because they received
fewer than four courses, 45 were excluded because their
disease progressed or they were unassessable after four
courses, and 39 were excluded because their responses were
not assessed after two courses. For the 320 patients, responses
were assessed after the second and fourth course of chemo-
therapy with computed tomography scans. Patients attaining
either complete response (CR), partial response (PR), or
stable disease (SD) were included in the study. All patients
provided written informed consent for the treatment received
as per local policy.
Treatment
All the patients received a platinum-based regimen, and
this was predominantly MVP (mitomycin C 6 mg/m2 intra-
venously [IV] on day 1, vinblastine 6 mg/m2 (maximum 10
mg) IV on day 1, and cisplatin 50 g/m2 IV on day 1 or
carboplatin if the Cockroft and Gault calculated glomerular
filtration rate was 60; no carboplatin if the Cockroft and
Gault calculated glomerular filtration rate was 30, every 21
days) in the majority of patients. This regimen has been
described in detail before.7 The other regimens used were
gemcitabine and carboplatin (gemcitabine 1250 mg/m2 on
days 1 and 8; carboplatin area under the curve [AUC] 5),
gemcitabine-cisplatin (gemcitabine 1250 mg/m2 on days 1
and 8; cisplatin 80 mg/m2), vinorelbine-carboplatin (vinorel-
bine 25 mg/m2, carboplatin AUC5), vinorelbine-cisplatin
(vinorelbine 30 mg/m2, cisplatin 80 mg/m2), Taxol-carbopla-
tin (paclitaxel 175 mg/m2, carboplatin AUC5 ), and mitomy-
cin C, cisplatin, 5-fluorouracil (mitomycin C 9 mg/m2, cis-
platin 75 mg/m2, continuous infusional 5-fluorouracil 200
mg/m2/24 hours by ambulatory pump and Hickman line).
Assessment of Objective Response
Tumor responses were assessed radiographically every
two cycles. Designations of CR, PR, no change/SD, and
progressive disease (PD) were based on the standardized
response definitions established by the World Health Orga-
nization.11 Symptom assessment was done by physicians in
the clinic and recorded in the notes; these data were then
entered in the database. Each symptom was recorded as
“gone–complete resolution/improved–partial resolution/
same–no change/worse–
progression of symptoms/not assessable.” These responses to
individual symptoms were then used to define the overall
response as it would be for objective response. This is not a
validated scale but was the same method used for a prospec-
tive randomized study comparing three to six courses in this
same patient population.7
Statistical Considerations
Patients were divided into three groups depending on their
response to chemotherapy after two and four courses (PR after
two courses and continued PR after four courses PR2PR4; SD
after two courses and PR after four courses SD2PR4; SD after
two courses and continued SD after four courses SD2SD4).
Differences in demographics and disease characteristics be-
tween the groups were assessed by the 2 and Mann-Whitney
tests. Overall survival (OS) was measured from the date of
first treatment until death. Progression-free survival (PFS)
was measured from the date of first treatment until progres-
sion or death and was censored at last follow-up. The influ-
ence of response after two and four courses on PFS and OS
was investigated in a univariate analysis using the Kaplan-
Meier12 method and log-rank statistic13 and also in a multi-
variate proportional hazard analysis. Variables included in
the multivariate analysis were age, sex, stage of disease,
pathology, and performance status. A step-up method was
used and variables added at the 0.05 level of significance. The
relative risk of death, together with its 95% confidence
interval (CI), was calculated for each group. Response after
two courses was added to the final model to determine its
independent significance. All analyses were done using SPSS
and all p values were two sided.
RESULTS
Patients:
Of 1041 NSCLC patients who had platinum-based
chemotherapy, 879 patients received two or more courses
(Figure 1). Of these, 624 were responding or had stabilization
of disease: 211 (24%) had a PR; 413 (46%) had SD; 338
patients went on to complete four courses of chemotherapy
with 320 achieving a response (n  156) or continued
stabilization (n  154). These 320 patients are, by definition,
a good prognosis group and the subject of this study.
The demography of the 320 patients is summarized in
Table 1. The median age of the patients was 60 years (range,
25–82), the majority of the patients had an Eastern Cooper-
ative Oncology Group performance status of 0–1 and had
adenocarcinoma. Of the 157 patients with stage III disease,
125 were stage IIIa/stage IIIb (dry) not suitable for radical
treatment by virtue of their poor lung function or volume or
location of disease. There were 32 (20%) patients with wet
stage IIIb disease. Patients were divided into two subgroups
for the purpose of the analysis (PR and SD after two courses).
There were no statistically significant differences between the
two groups apart from more patients with adenocarcinoma in
the SD group (p  0.05).
Treatment Administration
A total of 240 patients received MVP, 16 MCF, 15
vinrelbine-cisplatin, six gemcitabine-cisplatin, 10 Taxol-car-
boplatin, 14 vinrelbine-carboplatin, and 14 gemcitabine-car-
boplatin, and five others (platinum-based). The median num-
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ber of cycles of chemotherapy given was five (range, four to
eight), with responders receiving more courses in total than
those with SD (p  0.01).
Response Rates
After two courses of platinum-based chemotherapy,
115 of 320 (36%) patients attained a PR and 205 (64%) had
SD. After four courses, the patients with a PR continued to
have a PR, whereas of the 205 patients with SD, 51 (25%)
attained PR with further courses of chemotherapy and 154
(75%) had SD. There was no difference in the outcome of
these groups (Figure 2). Subsequently disease progressed in
two responders and 12 patients with SD on treatment. Pa-
tients who had an objective response after two courses had a
significantly better symptomatic response, as shown in Table
2 (p  0.003, Mann-Whitney) and also had a longer duration
of symptom response. The median duration of symptom
response in patients who attained a PR after two courses was
32 weeks (95% CI: 26–39) compared with 23 weeks (95%
CI: 18–28) in those with SD after two courses (p  0.04).
Second-Line or Salvage Treatment
At the time of progression, patients were considered for
second-line therapy. Among patients who attained a PR after
two courses, 26 of 115 (23%) received second-line therapy
compared with 46 of 205 (23%) patients who had attained SD
after two courses. The second-line regimens overall included
docetaxel in 12 patients, navelbine based in six, gemcitabine
based in four, Iressa in 19, Tarceva in 12, MVP in 11 patients,
and other regimens in eight. There was no imbalance in their
use between the two groups.
Survival
The median PFS and OS for this selected group of
patients receiving four or more courses of chemotherapy (n
320) were 28 weeks (95% CI: 26–30) and 42 weeks (95% CI:
39–45), respectively. In comparison, the median survival of
304 patients who had stabilization of disease after two
courses but are excluded from the current analysis (Figure 1)
was 31 weeks. Figure 2 shows the Kaplan-Meier overall
survival curves of patients based on response after two
courses. The PFS and OS are shown in Table 3 for the two
subgroups attaining PR and SD after two courses. The me-
dian survival was similar in the two groups (46 weeks versus
FIGURE 1. Consort diagram of patient denominator. PR,
partial response; SD, stable disease; chemo, chemotherapy,
NA, not assessed; PD, progressive disease.
TABLE 1. Patient Characteristics
Response After 2 Courses
of Platinum-Based
Chemotherapy
PR (n  115) SD (n  205) p






Squamous cell 40 30
















Other platinum 8 11





PR, partial response; SD, stable disease; PS, performance status; MVP, mitomycin
C, vinorelbine, cisplatin or carboplatin; Gem, gemcitabine; cis, cisplatin; carbo, carbo-
platin; Nav, navelbine.
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41 weeks), but the curves separated after this point, giving a
survival advantage to the responders (p  0.002).
As shown in Table 4, male sex (p  0.001) and stage
IV disease (p  0.001) also predicted a worse outcome in the
multivariate analysis. Cox regression analysis shows that
after adjusting for other prognostic factors like age, sex, and
stage, response after two courses of chemotherapy remains an
independently significant prognostic factor for survival. Fig-
ure 3 shows OS adjusted for age and sex for patients attaining
PR after two courses versus those with SD.
DISCUSSION
In this study of a subgroup of 320 patients receiving
four courses of platinum-based treatment, we were able to
show as an independent variable in a Cox multivariant anal-
ysis that patients who had responded after two courses of
therapy (and who went on to receive four courses) fared
better than those with SD after two courses.
Andre et al.14 showed that for patients with N2 NSCLC
who received preoperative chemotherapy, the 3-year event-
free survival rate after preoperative chemotherapy was 25%
for patients who achieved a CR or a PR and 7% for those who
did not (p  0.001), and the 5-year OS rates were 20% and
5%, respectively (p  0.001), suggesting that patients with
SD may be considered resistant to chemotherapy and treated
in a different manner. Recently, a paper presented at Amer-
ican Society of Clinical Oncology tried to answer the ques-
tion raised by this stud, although the study design was such
that patients attaining PR/SD after three courses of chemo-
therapy were then subsequently randomized to continuation
of the same chemotherapy or switched to a taxane.10 These
patients were initially treated with three courses of gemcit-
abine 1 g/m2, ifosfamide 3 g/m2, and cisplatin 50 mg/m2
(GIP) every 3 weeks, and patients with nonprogressing tumor
were randomized to three further courses or to three courses
of paclitaxel 225 mg/m2. The median survival was 14.1
months for the GIP arm and 16.4 months for the GIP-
paclitaxel arm (p 0.17). Another phase III trial of induction
therapy with four cycles of gemcitabine-carboplatin followed
by either delayed or immediate second-line therapy with
docetaxel in patients with advanced NSCLC showed that the
response rate and clinical benefit rate were higher with
immediate use of second-line therapy.15 In this study, after
four cycles of gemcitabine-carboplatin (gemcitabine 1 g/m2
day 1,8, carboplatin AUC 5 on day 1 every 3 weeks ), patients
with nonprogressing disease were randomized to immediate
docetaxel (75 mg/m2 on day 1 every 3 weeks) or delayed
docetaxel.15 The survival data have not been presented. Our
FIGURE 2. Log rank comparison of overall survival of pa-
tients based on response after two courses (PR2PR4: those
with a partial response (PR) after two courses who continued
to have a PR after four courses; SD2PR4: those with stable
disease (SD) after two courses and attained a PR after four
courses; SD2SD4: those with SD after two courses who con-
tinued to have SD after four courses). NSCLC, non-small cell
lung cancer.







(n  205) p
Complete resolution of symptoms 29 (25%) 27 (13%) 0.003
Resolution of majority of symptoms 68 (59%) 157 (76%)
No change in symptomatology 4 12
Worsening of symptoms 1 2
Symptomatology not recorded 13 7




PR After 2 Courses
(n  115)
SD After 2 Courses
(n  205)
Median PFS, wk (range) 28 (26–30) 32 (29–35) 26 (24–28)
1-yr 18% (95% CI: 13–23) 20% (95% CI: 12–28) 8% (95% CI: 2–13)
2-yr 5% (95% CI: 2–8) 17% (95% CI: 11–22) 4% (95% CI: 1–7)
Median OS, wk (range) 42 (39–45) 46 (34–57) 41 (37–44)a
1-yr 39% (95% CI: 33–44) 46% (95% CI: 37–56) 34% (95% CI: 28–41)
2-yr 14% (95% CI: 37–46) 21% (95% CI: 12–30) 11% (95% CI: 6–16)
PD, progressive disease; SD, stable disease; PFS, progression-free survival; OS, overall survival; CI, confidence interval.
a Those with a PR after two courses have a better OS and PFS than those with SD after two courses (OS, p  0.002; PFS, p  0.03).
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data suggest that these switches in treatment could be pro-
posed as early as after the second cycle of chemotherapy. It
is possible that for a group of patients, a noncytotoxic
approach or early use of second-line therapy may be better
suited compared with sequential salvage chemotherapy.
We have shown that 51 of 205 of our patients with SD
after two courses went on to respond after four courses, and
disappointingly their outcome was no different in terms of
survival and PFS when compared with those who did not
respond. This late PR was not as meaningful as the early PR.
Our data suggest that patients achieving an early PR have
better outcome and that SD after two courses may be the time
in a patient’s treatment pathway to consider second-line
therapy options. It has been shown in cancer treatment that
patients with objective tumor responses were more likely to
have a better quality of life than those patients where the best
overall response was SD or PD.16
Current American Society of Clinical Oncology guide-
lines for unresectable stage III/IV NSCLC recommend four to
six courses of chemotherapy with a maximum of four courses
in nonresponding patients.17
Our study challenges the current norm of continuation
of treatment in patients with NSCLC who have stable disease
after two cycles of first-line platinum-based chemotherapy,
which is currently the standard of care. It may be more
important that we individualize treatment for patients with
NSCLC to improve outcome. Data from Rosell et al.18
demonstrated that overexpression of ERCC1 and other nu-
cleotide excision repair enzymes may have an impact on
cisplatin resistance. Based on this, an early switch to non-
platinum-based regimens might be indicated early on during
the treatment pathway for some patients.
Another way forward may be to assess metabolic re-
sponse ([18F]fluorodeoxyglucose uptake by using positron
emission tomography [PET]) within the subgroup of patients
who have stable disease after two courses to decide on further
continuation of that chemotherapy. This would involve PET
for response assessment after completing two cycles of che-
motherapy to see whether they have attained a degree of
functional response rather than an anatomical response. PET
may have a role in better assessment and prediction of
response. Preliminary data have been published to indicate
that the percentage of [18F]fluorodeoxyglucose uptake after
one and three courses of induction chemotherapy predicts
survival in stage IIIA-N2 patients.19
We are aware of the limitations of this study. This is a
retrospective study in a selected group of heterogeneously
treated patients over a long period who had to be well enough
to receive the fourth cycle of chemotherapy. The PFS and the
median duration of symptom response in this study is longer
because of preselection criteria for these patients to have had
already survived progression free for four courses of treat-
ment (approximately 12 weeks). The majority of patients
received the triplet regimen MVP, which is not the current
standard practice, and only 18.4% patients received the third-
generation chemotherapy. However, the treatment was all
given in a standard way at a single cancer center with long
follow-up. Our data on the 320 patients with SD after two
courses includes only those patients who received four
courses, but patients appear well balanced for established
prognostic factors. This point of intervention, SD after two
courses, could become a point when biopsy could be per-
formed again on tumors and phase II development work
carried out to help predict a phenotypically or genotypically
led treatment.
In conclusion, NSCLC patients with SD after two
courses of initial first-line chemotherapy have a poorer out-
come than those with a PR and hence should be considered
for reassessment possibly with a PET scan and entered into
trials of alternative second-line treatment strategies. A pro-
spective randomized trial in a homogeneous group of ad-
vanced NSCLC patients with special consideration to salvage
treatment is required.
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